PureTech Health (LON:PRTC) Trading 14.2% Higher - Still a Buy?

Key Points

• PureTech Health shares rose by 14.2% on Friday, with trading volumes significantly up at approximately 9 million shares.
• The company's market cap stands at £293.65 million, while it has a high PE ratio of 714.71 and a debt-to-equity ratio of 45.82.
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1, reflecting confidence in the company's potential.

PureTech Health plc (LON:PRTC - Get Free Report) traded up 14.2% during mid-day trading on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares changed hands during mid-day trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Trading Up 4.2%

The business's fifty day moving average is GBX 129.46 and its 200-day moving average is GBX 129.72. The firm has a market cap of £303.07 million, a P/E ratio of 737.65 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

Insider Transactions at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction on Thursday, July 3rd. The stock was purchased at an average price of GBX 1 per share, for a total transaction of £1,677.39. Insiders own 13.13% of the company's stock.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.